Business
Natera Releases New Clinical Data at ESMO 2021 in Gastroesophageal Cancer and Uveal Melanoma
Data suggests that ctDNA dynamics may be a better surrogate of overall survival than radiographic imaging (RECIST criteria) AUSTIN, Texas, Sept. 17, 2021
About this update from Natera, Inc.
[{"type":"text","content":"Data suggests that ctDNA dynamics may be a better surrogate of overall survival than radiographic imaging (RECIST criteria)\n\n\nAUSTIN, Texas, Sept. 17, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, today announced new data being presented by the company and its collaborators on the use of the Signatera® personalized molecular residual disease (MRD) technology at the 2021 European Society for Medical Oncology (ESMO) Congress, taking place September 16–21, 2021. \n\n \n \n \n \n \n \n\n \nIn three new studies, Natera will present the real-world clinical performance of Signatera in esophageal and gastric cancers, the power of ctDNA dynamics for assessing treatment response in uveal melanoma and the correlation of CHIP mutations with patient outcomes.\n\"Results from our study indicate that ctDNA is highly predictive of relapse in patients with gastroesophageal cancer,\" said Brandon Huffman, M.D., clinical oncology fellow at Dana Farber Cancer Institute and Massachusetts General Hospital Cancer Center, and first author of the study. \"Most gastroesophageal cancers recur after definitive treatment, and patients with advanced disease have a poor overall prognosis. This study addresses a huge need for tools to better identify patients at risk of recurrence and to inform disease management.\"\n\"This data underscores the value of tumor-informed MRD assessment in GI cancers,\" said Alexey Aleshin, M.D., Natera's VP of medical affairs, oncology. \"It also highlights the potential for Signatera to improve upon radiographic imaging as a clinical endpoint, which can accelerate drug development and improve patient care.\"\nDetails about the presentations are as follows:\nPerformance of a tumor-informed circulating tumor DNA assay from over 260 patients with over 800 plasma time points in esophageal and gastric cancerOn-Demand ePoster: 1415PPresenter: Griffin L. Budde, Natera, Inc.\nThis study used Signatera for the detection and quantification of ctDNA in a prospective real-world cohort of 886 plasma samples from 269 patients with gastroesophageal cancer. Serial time points were collected in a subset of patients to monitor ctDNA levels after curative intent therapy. Analysis showed tumor-informed ctDNA status is highly predictive of relapse in patients with stage I-IV disease, with ctDNA detected in 9...